A Double Mutation in Glycoprotein GB Compensates for Ineffective GD-dependent Initiation of Herpes Simplex Virus Type 1 Infection
Overview
Authors
Affiliations
Herpes simplex virus (HSV) entry into cells is triggered by the binding of envelope glycoprotein D (gD) to a specific receptor, such as nectin-1 or herpesvirus entry mediator (HVEM), resulting in activation of the fusion effectors gB and gH and virus penetration. Here we report the identification of a hyperactive gB allele, D285N/A549T, selected by repeat passage of a gD mutant virus defective for nectin-1 binding through cells that express a gD-binding-impaired mutant nectin-1. The gB allele in a wild-type virus background enabled the use of other nectins as virus entry receptors. In addition, combination of the mutant allele with an epidermal growth factor receptor (EGFR)-retargeted gD gene yielded dramatically increased EGFR-specific virus entry compared to retargeted virus carrying wild-type gB. Entry of the gB mutant virus into nectin-1-bearing cells was markedly accelerated compared to that of wild-type virus, suggesting that the gB mutations affect a rate-limiting step in entry. Our observations indicate that ineffective gD activation can be complemented by hypersensitization of a downstream component of the entry cascade to gD signaling.
Suzuki T, Uchida H Mol Ther Oncol. 2024; 32(2):200803.
PMID: 38706990 PMC: 11067338. DOI: 10.1016/j.omton.2024.200803.
Seek and destroy: Development of novel viral therapy for EGFR-expressing tumors.
OConnor C, Lathia J Mol Ther Oncol. 2024; 32(1):200776.
PMID: 38596292 PMC: 10915779. DOI: 10.1016/j.omton.2024.200776.
Oncolytic herpes simplex viruses designed for targeted treatment of EGFR-bearing tumors.
Ingusci S, Hall B, Cohen J, Glorioso J Mol Ther Oncol. 2024; 32(1):200761.
PMID: 38596286 PMC: 10869753. DOI: 10.1016/j.omton.2024.200761.
Novel mutations in U24 and gH rescue efficient infection of an HSV vector retargeted to TrkA.
Marzulli M, Hall B, Zhang M, Goins W, Cohen J, Glorioso J Mol Ther Methods Clin Dev. 2023; 30:208-220.
PMID: 37519407 PMC: 10384243. DOI: 10.1016/j.omtm.2023.06.012.
Sanchez Gil J, Dubois M, Neirinckx V, Lombard A, Coppieters N, DArrigo P Mol Ther Oncolytics. 2022; 26:35-48.
PMID: 35784400 PMC: 9217993. DOI: 10.1016/j.omto.2022.06.002.